Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) regularly issues news updates that focus on the development and evaluation of its patented DehydraTECH™ oral drug delivery platform. Company press releases highlight progress in human and animal studies, capital raising activities, strategic partnerships, and expansion of its intellectual property portfolio. For followers of LEXXW, this news flow offers insight into how DehydraTECH is being tested and positioned within the pharmaceutical landscape.
A major theme in Lexaria’s recent news is its work with GLP‑1 drugs such as semaglutide, tirzepatide, and liraglutide. The company reports results from multiple human pilot studies and a Phase 1b study in Australia (GLP‑1‑H24‑4), where DehydraTECH‑processed oral formulations are compared against established injectable or oral products. These releases detail safety and tolerability outcomes, reductions in total and gastrointestinal adverse events, and comparative performance on measures like HbA1c, body weight, body composition, and pharmacokinetics.
News items also cover exploratory findings with DehydraTECH‑CBD, including reported blood pressure reductions in a clinical study arm, and pre-clinical work such as a fluorescently tagged semaglutide rodent biodistribution study. Beyond R&D, Lexaria’s announcements describe registered direct offerings on Nasdaq, concurrent warrant placements, and the intended use of proceeds to fund research, working capital, and general corporate purposes.
Additional updates include the extension of a Material Transfer Agreement with a pharmaceutical company to evaluate DehydraTECH, the engagement of a global life science business development advisory firm, and the issuance of new patents in areas such as diabetes, epilepsy, and antiviral treatments. Investors and observers monitoring LEXXW news can use these releases to track Lexaria’s clinical progress, partnering discussions, financing activities, and the evolution of its DehydraTECH-focused strategy over time.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announces a strategic update as CEO Chris Bunka steps down. Key points include:
- New focus on pharmaceutical studies in cardiometabolic and GLP-1 sectors
- Appointment of Richard Christopher as new CEO with pharma/biotech operations experience
- FDA clearance for Phase 1b hypertension study using DehydraTECH-CBD
- Over $8.5 million raised in 2024 through equity raises and warrant exercises
- Market cap growth from $5 million in June 2023 to $60 million
- Ongoing GLP-1 studies with promising results
- Plans for two Phase 1 studies in 2025
- Material Transfer Agreement with a pharmaceutical company
Bunka will continue as Executive Strategic Advisor and Chairman of the Board.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announces a significant leadership change, with Richard Christopher appointed as the new CEO, effective August 31, 2024. Christopher, an industry veteran with over 30 years of experience in medical devices and pharmaceuticals, replaces Chris Bunka, who will remain as Chairman of the Board and Executive Strategic Advisor. The transition aligns with Lexaria's focus on advancing drug delivery in the GLP-1 marketplace and pharmaceutical industry collaborations.
The company's 100-day plan includes executing a Material Transfer Agreement with a pharmaceutical company, ongoing GLP-1 research studies, and preparing for a 2025 FDA-cleared Phase 1b hypertension study. Lexaria's DehydraTECH™ technology, developed since 2015, aims to enhance drug delivery kinetics, with a focus on cardio-metabolic, diabetes, weight loss, and hypertension sectors.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has entered into a Material Transfer Agreement with a pharmaceutical company, referred to as 'PharmaCo'. The agreement aims to evaluate Lexaria's DehydraTECH technology in a pre-clinical setting. Under the terms:
1. Lexaria will formulate and supply specific DehydraTECH compositions.
2. PharmaCo will conduct animal studies to evaluate the pharmacokinetics of these compositions.
3. PharmaCo has been granted a temporary exclusive license option for specific DehydraTECH concepts and formulations under examination.
The evaluation process is expected to be completed within approximately 6 months or less. This agreement represents a significant step for Lexaria in advancing its drug delivery platform technology.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced positive results from its second GLP-1 human pilot study (GLP-1-H24-2) on DehydraTECH-processed Rybelsus® oral capsules. Key findings include:
1. Superior tolerability: None of the 9 participants taking DehydraTECH-processed Rybelsus® capsules experienced adverse events, compared to 6 out of 9 taking standard Rybelsus® tablets.
2. Improved absorption: DehydraTECH-processed Rybelsus® capsules showed 106.9% blood concentration levels compared to standard Rybelsus® tablets.
3. Novel delivery method: A DehydraTECH-processed Rybelsus® mouth-melt format showed promising results, delivering about one-third of the drug concentration of standard tablets.
These findings suggest that Lexaria's DehydraTECH technology could potentially enhance the oral delivery and tolerability of GLP-1 drugs like semaglutide, which may lead to increased use of oral GLP-1 products in the future.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced initial results from its second GLP-1 human pilot study, GLP-1-H24-2. The study compared DehydraTECH-processed Rybelsus to standard Rybelsus under fed conditions. Key findings include:
1. DehydraTECH-processed Rybelsus showed 18.8% higher average semaglutide levels over 24 hours.
2. Higher semaglutide levels were observed in 17 out of 19 blood draws.
3. The study used 7 mg semaglutide doses in both arms.
4. Results were not statistically significant due to small sample size.
These findings complement an earlier study showing a 43% peak blood level improvement under fasted conditions. Lexaria plans to continue its 2024 GLP-1 program with ongoing animal studies and a planned 12-week chronic human study.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has released 8-week body weight results from its ongoing animal study WEIGHT-A24-1. The study evaluates the performance of DehydraTECH-processed liraglutide and semaglutide, as well as various DehydraTECH-CBD formulations. Key findings include:
1. DehydraTECH-liraglutide (Group H) showed the most significant weight loss at -4.74%.
2. Two DehydraTECH-CBD formulations (Groups B and C) outperformed DehydraTECH-semaglutide and Rybelsus compositions.
3. All DehydraTECH drug therapies resulted in weight decreases or slower weight gain compared to the initial acclimation phase.
The study is ongoing, with additional results expected. Lexaria cautions against direct comparisons to human weight loss studies due to the unlimited food and water provided to the animals.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced positive interim blood sugar results from its ongoing GLP-1 diabetes animal study WEIGHT-A24-1. Key findings include:
1. DehydraTECH-liraglutide and two DehydraTECH-CBD formulations showed the best performance at day 56, with blood sugar level reductions of 2.50%, 1.90%, and 1.53% respectively.
2. All 8 active groups experienced smaller increases or actual decreases in blood sugar levels compared to the obese control group from a previous study.
3. DehydraTECH-liraglutide outperformed DehydraTECH-semaglutide, which is notable as semaglutide typically outperforms liraglutide in human studies without DehydraTECH processing.
The study is ongoing, with additional results expected soon.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced positive results from its molecular characterization study of DehydraTECH-processed semaglutide, a GLP-1 drug. The study, conducted with the National Research Council of Canada, compared DehydraTECH-processed pure semaglutide to the commercial formulation Rybelsus®. Key findings include:
1. Semaglutide was efficiently released in simulated gastric fluid.
2. The drug likely remained in monomeric form, similar to Rybelsus®.
3. DehydraTECH achieved monomeric form without using SNAC, a proprietary ingredient in Rybelsus®.
This is significant as the monomeric form allows for better permeation of the gastric epithelium. The results suggest DehydraTECH's potential in oral GLP-1 drug delivery, a market where Novo Nordisk paid ~$1.8 billion for SNAC technology in 2020.
Lexaria Bioscience Corp. (Nasdaq: LEXX) reports positive interim results from its diabetes animal study WEIGHT-A24-1. After 28 days of dosing, DehydraTECH-processed drug therapies showed decreased body weight gain or weight reduction. Key findings include:
1. DehydraTECH-CBD formulation 3 and DehydraTECH-liraglutide produced the largest weight loss: -1.50% and -1.58% respectively.
2. DehydraTECH appears effective with both semaglutide and liraglutide.
3. DehydraTECH-processed pure semaglutide performed similarly to reformulated Rybelsus® with SNAC technology.
4. Dosing for the final four study arms has begun, including combinations of DehydraTECH-processed drugs.
The study aims to explore potential enhancements in brain absorption and glucose control. Full results, including blood glucose and pharmacokinetic data, are pending.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced plans for strategic growth. The company is expanding its management team, starting with the appointment of Nelson Cabatuan as consulting Chief Strategic Financial Advisor. Cabatuan is resigning from his role as CFO to focus on strategic opportunities. A new CFO will be announced soon.
Lexaria is also exploring additional R&D projects related to GLP-1 molecules beyond those previously disclosed. The company is considering concrete steps to launch its FDA-cleared Phase 1b hypertension study, subject to funding. CEO Chris Bunka expressed increased confidence in the company's medium and long-term strategies due to ongoing success and anticipated future achievements.